Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine

Georges, A. J.; Tible, F.; Meunier, Danièle; Gonzalez, Jean-Paul; Beraud, A. M.; Sissoko-Dybdahl, N.-R.; Abdul-Wahid, S.; Fritzell, Bernard; Girard, Marc; Georges-Courbot, M.-C.

doi:10.1016/s0264-410x(85)90182-3

Cited by 21 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies performed in children older than 12 months of age have reported post-vaccination seropositivity rates against YF of 94% in the Central African Republic ( Georges et al 1985 ), 94.7% in Mali ( Soula et al 1991 ) and 94.6-96.6% in Peru (Vacina Arilvax ® ) ( Belmusto-Worn et al 2005 ).…”

Section: Discussionmentioning

confidence: 98%

A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old

2015

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

This randomised, double-blind, multicentre study with children nine-23 months old evaluated the immunogenicity of yellow fever (YF) vaccines prepared with substrains 17DD and 17D-213/77. YF antibodies were tittered before and 30 or more days after vaccination. Seropositivity and seroconversion were analysed according to the maternal serological status and the collaborating centre. A total of 1,966 children were randomised in the municipalities of the states of Mato Grosso do Sul, Minas Gerais and São Paulo and blood samples were collected from 1,714 mothers. Seropositivity was observed in 78.6% of mothers and 8.9% of children before vaccination. After vaccination, seropositivity rates of 81.9% and 83.2%, seroconversion rates of 84.8% and 85.8% and rates of a four-fold increase over the pre-vaccination titre of 77.6% and 81.8% were observed in the 17D-213/77 and 17DD subgroups, respectively. There was no association with maternal immunity. Among children aged 12 months or older, the seroconversion rates of 69% were associated with concomitant vaccination against measles, mumps and rubella. The data were not conclusive regarding the interference of maternal immunity in the immune response to the YF vaccine, but they suggest interference from other vaccines. The failures in seroconversion after vaccination support the recommendation of a booster dose in children within 10 years of the first dose.

show abstract

Section: Discussionmentioning

confidence: 98%

A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old

2015

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…Media such as lactose, sorbitol, histidine and alanine have considerably improved the heat stability of lyophilized 17D yellow fever (YF) vaccine (127). These stabilized vaccines may successfully be used in different field conditions (51,118).…”

Section: Stability Of Freeze-dried Vaccinementioning

confidence: 99%

Effect of Freezing on Oxytocin Ampules

2013

View full text Add to dashboard Cite

“…In 1942, there were cases of hepatitis in England, Brazil, and the United States due to the practice of adding 10% human serum to the vaccine, which was contaminated with a hepatitiscausing virus, as this was necessary for stability of the vaccine virus . In Brazil, there were a few cases of encephalitis in children, depending on which substrain was utilized to vaccinate them; 0.36% of vaccinees showed CNS involvement and one person died ( Georges et al, 1985 ). By 1945 the Standing Technical Committee on Health of the United Nations Relief and Rehabilitation Administration established manufacturing standards to control vaccine production ( WHO, 1945 ;United Nations Relief and Rehabilitation Administration 1946).…”

Section: Immune Response To Infectionmentioning

confidence: 99%

“…After the suspension is freeze-dried, it is placed in nitrogen-filled flame-sealed ampoules and stored at 0 -5 ° C temperature. Some producers include stabilizers, such as gelatin, peptone, lactose, sorbitol, histidine, or alanine, with the vaccine to maintain the viability of the vaccine at high temperatures such as that found in tropical countries ( De Souza Lopes et al, 1988a ;Barmr and Bronnert, 1984 ;Georges et al, 1985 ). Once produced, the WHO has designated control tests that must be carried out to determine vaccine potency.…”

Section: Agent/strain Used In Vaccine How Produced Number Of Doses mentioning

confidence: 99%

Yellow Fever

Galbraith

Barrett

2009

Vaccines for Biodefense and Emerging and Neglected Diseases

View full text Add to dashboard Cite

Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine

Cited by 21 publications

References 2 publications

A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old

A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old

Effect of Freezing on Oxytocin Ampules

Yellow Fever

Contact Info

Product

Resources

About